Literature DB >> 31487685

Fine-Needle Aspiration Biopsy of Liver Lesions Yields Higher Tumor Fraction for Molecular Studies: A Direct Comparison With Concurrent Core Needle Biopsy.

Patricia Ellen Goldhoff1, Poonam Vohra2, Kanti Pallav Kolli3, Britt-Marie Ljung1.   

Abstract

BACKGROUND: This retrospective study evaluated and compared the diagnostic accuracy and suitability of tissue specimens for advanced molecular diagnostic testing obtained via 2 different techniques for percutaneous biopsy of primary and metastatic liver tumors. PATIENTS AND METHODS: Samples from 137 patients with liver masses who underwent concurrent fine-needle aspiration biopsy with cell block (FNAB-CB) and core needle biopsy (CNB) at 2 hospitals were assessed for diagnostic accuracy, tumor fraction, and tumor cellularity. A subset of FNAB-CBs, that were deemed to have less or equal tumor cellularity compared with CNBs, had level sections performed and were reassessed for tumor cellularity.
RESULTS: Diagnostic accuracy was 96% for FNAB and 93% for CNB (P=.267). In FNAB-CBs, tumor fraction was significantly higher than in CNB samples (67% vs 36%; P<.0001), whereas nontumor components were significantly lower (stromal component, 7% vs 29%; P<.0001; background benign hepatocytes, 25% vs 36%; P=.003). Additionally, in 44% of cases, FNAB-CB tumor cellularity was equal to or greater than that of the concurrent CNB.
CONCLUSIONS: In the current age of personalized medicine, a minimally invasive, safe approach to obtaining adequate tissue for myriad molecular testing is paramount. We have shown that FNAB sampling is diagnostically accurate and produces higher tumor fractions than CNB. Thus, FNAB should be strongly considered as an initial sampling modality, especially for patients in whom molecular tests will determine management.

Entities:  

Mesh:

Year:  2019        PMID: 31487685     DOI: 10.6004/jnccn.2019.7300

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  4 in total

1.  Variability in biopsy quality informs translational research applications in hepatocellular carcinoma.

Authors:  Kelley Weinfurtner; Joshua Cho; Daniel Ackerman; James X Chen; Abashai Woodard; Wuyan Li; David Ostrowski; Michael C Soulen; Mandeep Dagli; Susan Shamimi-Noori; Jeffrey Mondschein; Deepak Sudheendra; S William Stavropoulos; Shilpa Reddy; Jonas Redmond; Tamim Khaddash; Darshana Jhala; Evan S Siegelman; Emma E Furth; Stephen J Hunt; Gregory J Nadolski; David E Kaplan; Terence P F Gade
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.996

2.  An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.

Authors:  David C Madoff; Nadine Abi-Jaoudeh; David Braxton; Lipika Goyal; Dhanpat Jain; Bruno C Odisio; Riad Salem; Mark Schattner; Rahul Sheth; Daneng Li
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

3.  Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids.

Authors:  Anna E Vilgelm; Kensey Bergdorf; Melissa Wolf; Vijaya Bharti; Rebecca Shattuck-Brandt; Ashlyn Blevins; Caroline Jones; Courtney Phifer; Mason Lee; Cindy Lowe; Rachel Hongo; Kelli Boyd; James Netterville; Sarah Rohde; Kamran Idrees; Joshua A Bauer; David Westover; Bradley Reinfeld; Naira Baregamian; Ann Richmond; W Kimryn Rathmell; Ethan Lee; Oliver G McDonald; Vivian L Weiss
Journal:  iScience       Date:  2020-07-24

Review 4.  Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach.

Authors:  May T Cho; Sepideh Gholami; Dorina Gui; Sooraj L Tejaswi; Ghaneh Fananapazir; Nadine Abi-Jaoudeh; Zeljka Jutric; Jason B Samarasena; Xiaodong Li; Jennifer B Valerin; Jacob Mercer; Farshid Dayyani
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.